Litigation Details for Amgen Inc. v. USV Private Limited (D. Del. 2022)

Amgen Inc. v. USV Private Limited (D. Del. 2022)

Docket		Date Filed	2022-03-25
Court	District Court, D. Delaware	Date Terminated	2023-11-14
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,344,765; 11,162,500; 9,820,938
Link to Docket	External link to docket

Details for Amgen Inc. v. USV Private Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-03-25				External link to document
2022-03-25	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,820,938 B2, 10,344,765 B2, and 11,… 14 November 2023 1:22-cv-00387 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Amgen Inc. v. USV Private Limited, 1:22-cv-00387: Litigation Summary and Patent Analysis

Last updated: August 4, 2026

Amgen Inc. v. USV Private Limited, No. 1:22-cv-00387, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware involving USV's abbreviated new drug application for generic apremilast tablets, the active ingredient in Amgen's Otezla product. Amgen asserted patents covering apremilast and its crystalline form. The case did not produce a reported validity or infringement decision. The public docket reflects a resolution and dismissal rather than a trial judgment. The commercial significance was the potential generic entry date for apremilast, a product with multibillion-dollar annual sales.

What drug and patents were involved in Amgen v. USV?

The case concerned apremilast tablets in the strengths corresponding to Otezla's approved dosage forms. Otezla is approved for:

• Psoriatic arthritis
• Moderate-to-severe plaque psoriasis
• Oral ulcers associated with Behçet's disease

Amgen acquired Otezla through its 2019 acquisition of Celgene's psoriasis product portfolio. The asserted patent estate originated with Celgene-related entities and transferred to Amgen as part of that transaction.

Case identification

Item	Detail
Case	Amgen Inc. v. USV Private Limited
Court	U.S. District Court for the District of Delaware
Civil action	1:22-cv-00387
Filing period	2022
Plaintiff	Amgen Inc.
Defendant	USV Private Limited
Legal framework	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)
Product	Generic apremilast tablets
Reference product	Otezla
Regulatory pathway	ANDA
Disposition	Resolved and dismissed; no reported merits judgment

The case was filed after USV notified Amgen of a Paragraph IV certification challenging listed Otezla patents. A Paragraph IV certification alleges that the relevant patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

What patents protect Otezla and apremilast?

The principal Otezla patent protection included patents covering the apremilast compound, crystalline forms, pharmaceutical compositions, and treatment methods. The patents asserted against USV were associated with the later-expiring crystalline-form and related product protection rather than only the original compound patent.

Core Otezla patent categories

Patent category	Protection	Commercial relevance
Compound patent	Apremilast chemical entity	Foundational protection; earlier expiration
Solid-state patent	Crystalline apremilast form	Protects the form used in commercial tablets
Composition patent	Apremilast pharmaceutical compositions	Addresses tablet formulation and drug product
Method-of-use patent	Treatment of psoriasis and related conditions	Can create additional infringement theories
Regulatory listing	Orange Book patents	Supports Hatch-Waxman enforcement against ANDA applicants

Publicly identified Otezla patent records include U.S. Patent No. 6,962,940 and U.S. Patent No. 8,193,197. Other Otezla-related patents have been associated with methods of treatment and product protection, including U.S. Patent No. 8,404,722. The relevant patent set can vary by dosage form, indication, and the Orange Book listing in effect when an ANDA is filed.

Patent expiration timeline

Protection	Approximate status
Original apremilast compound protection	Expired or near expiration before the USV case
Crystalline-form protection	Extended protection into the late 2020s
Method-of-use protection	Potentially extended into the late 2020s, subject to claim scope and listing
Regulatory exclusivity	No independent long-term exclusivity comparable to the later patent terms

The commercial blocking position for Otezla depended primarily on the later-expiring patents. The original compound patent alone was not sufficient to prevent a modern generic filing if the generic applicant could certify that the remaining listed patents were invalid or not infringed.

What was the legal basis of Amgen's lawsuit against USV?

Amgen filed the action under Section 271(e)(2) of the Patent Act. Filing an ANDA with a Paragraph IV certification is treated as an artificial act of infringement for purposes of resolving patent disputes before commercial launch.

Amgen's claims likely focused on the following issues:

1. Whether USV's proposed apremilast product would practice claims covering a protected crystalline form.
2. Whether the generic tablet would infringe composition or formulation claims.
3. Whether USV's proposed labeling would induce infringement of patented treatment methods.
4. Whether the asserted patents were valid and enforceable.
5. Whether USV's Paragraph IV certifications were legally sufficient.

The case was therefore a pre-launch dispute. USV was not accused of selling an infringing product in the market. The litigation was designed to determine whether commercial launch could occur before the asserted patents expired or before an agreed settlement date.

What was the Paragraph IV challenge in the USV case?

USV's ANDA challenged the listed Otezla patents through Paragraph IV certifications. The certifications placed the burden on Amgen to bring suit within 45 days of receiving notice. Amgen's filing triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to earlier termination or other court action.

Hatch-Waxman timing

Event	Effect
USV files ANDA	Seeks FDA approval for generic apremilast
USV sends Paragraph IV notice	Notifies Amgen of patent challenge
Amgen files suit	Preserves patent litigation rights
FDA approval stay begins	FDA generally cannot approve the ANDA for 30 months
Settlement or judgment	May permit earlier approval or establish a launch date

The case number indicates a 2022 filing. Absent an earlier termination, a standard 30-month stay would have extended into approximately 2024. The actual approval and launch consequences depended on the settlement terms, FDA action, and the status of each listed patent.

What was the litigation status and outcome?

The case did not result in a published claim-construction order, infringement judgment, or final invalidity decision that established precedent for apremilast patent litigation. The public record indicates that the parties resolved the dispute and dismissed the action.

The material outcome is therefore commercial rather than precedential:

• Amgen did not obtain a reported merits judgment against USV.
• USV did not obtain a reported invalidity judgment against the asserted patents.
• The public docket does not disclose the complete economic terms of the resolution.
• The settlement likely addressed the earliest permissible generic launch date and related regulatory obligations.
• The resolution reduced immediate litigation risk for both parties.

A dismissal following settlement does not establish that the asserted patents were valid, infringed, or enforceable. It also does not establish that USV's product would have avoided infringement. The parties' agreement, rather than a judicial merits determination, controlled the practical launch outcome.

Did the case involve a settlement agreement?

Yes. The case was resolved without a public trial decision. Hatch-Waxman settlements commonly include:

• A permitted generic entry date
• A license to listed patents
• Restrictions on launch before a negotiated date
• Provisions addressing authorized generic competition
• Covenants not to sue
• Confidential commercial terms
• Allocation of responsibility for FDA communications

The public docket generally may show dismissal papers without revealing the full settlement agreement. Under the Medicare Modernization Act, brand and generic companies must submit certain agreements to the Federal Trade Commission and Department of Justice. Submission does not make every economic term publicly available in the court docket.

A settlement is not equivalent to a judgment that the patents would withstand an invalidity challenge. Its value lies in converting litigation uncertainty into a negotiated launch framework.

What is the Orange Book status of Otezla?

Otezla's patent protection is reflected through FDA Orange Book listings for the approved drug product. Orange Book-listed patents can trigger the Hatch-Waxman certification process when a generic applicant seeks approval for the same drug.

The relevant Orange Book issues include:

• Whether each patent was listed for the relevant Otezla product
• Whether the patent covered the product, formulation, or method of use
• Whether USV made a Paragraph IV or alternative certification
• Whether a listed method-of-use patent affected the proposed labeling
• Whether patent delisting or expiration changed the FDA approval timetable

Orange Book listing is a regulatory status, not a final determination of patent validity. The FDA does not decide whether the listed patent is infringed or enforceable.

How strong was Amgen's patent estate against USV?

Amgen's estate was stronger as a layered product-protection strategy than as a single compound-patent position.

Strengths

• Later-expiring crystalline-form patents could extend protection beyond the original compound patent.
• Apremilast tablets were likely designed around a specific solid form, making solid-state claims commercially relevant.
• Product and method-of-use claims created multiple litigation theories.
• The ANDA filing allowed Amgen to obtain a pre-launch judicial forum.
• Otezla's sales created a strong economic incentive to defend the patent estate.

Weaknesses

• The foundational compound patent had limited remaining life by the time of the 2022 litigation.
• Crystalline-form patents can face invalidity challenges based on anticipation, obviousness, and inadequate written description.
• Method-of-use claims may be vulnerable to skinny-label strategies.
• A generic applicant can challenge claim scope without copying every aspect of the branded product.
• Settlement eliminates the opportunity to establish enforceability through a court judgment.

The absence of a merits opinion leaves the ultimate strength of the asserted patents unresolved. The settlement demonstrates that the patents had sufficient commercial value to support negotiated resolution, but it does not quantify their litigation probability of success.

When could generic apremilast enter the market?

The negotiated launch date was not established by a reported judicial opinion in the case. Generic entry depended on several dates:

1. Expiration of the last enforceable patent blocking the ANDA.
2. The settlement's permitted launch date.
3. FDA approval after the 30-month stay.
4. Any pediatric-exclusivity extension.
5. The status of other Otezla patent litigation and settlements.
6. USV's commercial readiness and manufacturing approval.

The practical market entry date could therefore differ from the nominal expiration date of any single patent. A generic applicant may receive FDA approval before commercial launch if the settlement delays marketing.

Which companies were challenging Otezla patents?

Otezla became a target for multiple generic applicants because of its high sales and oral small-molecule structure. Companies involved in apremilast patent challenges have included Indian and U.S.-based generic manufacturers and their subsidiaries. The competitive field can change as applicants settle, withdraw, receive FDA approval, or launch under separate agreements.

The USV case should be analyzed alongside other Otezla ANDA cases because one settlement does not necessarily establish the launch position of every generic applicant. Each applicant may have different certifications, formulations, dosage strengths, and settlement rights.

What commercial exposure did the litigation create for Amgen?

Otezla was one of Amgen's largest products after the Celgene transaction. The product generated approximately $2 billion or more in annual revenue in the years surrounding the USV litigation, depending on the reporting period and exchange-rate effects [Amgen, 2023].

Generic apremilast entry would affect Amgen through:

• Price erosion
• Loss of pharmacy benefit placement
• Reduced market share
• Lower net sales
• Potential substitution across psoriasis and psoriatic arthritis prescriptions
• Pressure on the broader oral immunology market

The first generic entrant typically captures disproportionate share, but the magnitude of erosion depends on the number of approved applicants, launch timing, authorized generic supply, rebates, and payer substitution rules.

How does Otezla patent risk compare with biologic products?

Otezla is a small-molecule drug regulated through the ANDA pathway. Its generic risk is therefore more direct and usually faster once patent barriers fall.

Issue	Otezla	Amgen biologics
Approval route	ANDA	Biologics license application and biosimilar pathway
Primary challenge	Paragraph IV patent certification	Patent dance and biosimilar litigation
Product substitution	Generally easier after approval	Depends on interchangeability and state law
Manufacturing barrier	Chemical synthesis and solid-state control	Cell line, process, analytics, and scale-up
Litigation focus	Compound, crystal, formulation, use claims	Composition, formulation, manufacturing, and biologic-process claims
Entry economics	Potentially rapid generic price erosion	Usually slower and more limited biosimilar erosion

USV's case did not involve biosimilar risk. It involved a conventional generic drug application and small-molecule patent litigation.

What manufacturing and IP barriers affected USV?

The most important technical barrier was likely control of apremilast's solid-state form and tablet composition. A crystalline-form patent can create a manufacturing constraint if the commercially viable product necessarily uses the claimed polymorph. USV could respond by:

• Producing a non-infringing polymorph
• Using a different crystallization process
• Modifying excipients or dosage-form design
• Pursuing a non-infringement position based on claim construction
• Challenging the patent's validity

Manufacturing workarounds must still satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, stability, dissolution, and quality control. A formulation design that avoids one patent may create a separate regulatory or manufacturing burden.

What geographic coverage did the case provide?

The action covered U.S. patent rights and U.S. FDA approval. It did not determine:

• Patent rights in India
• European apremilast exclusivity
• Canadian launch rights
• International manufacturing rights
• Non-U.S. settlement obligations

USV's status as an Indian company was relevant to corporate identity and manufacturing structure, but the case itself was governed by U.S. patent and FDA law. Separate national proceedings would be required to assess foreign launch risk.

Key Takeaways

• Amgen Inc. v. USV Private Limited, 1:22-cv-00387, was a Delaware Hatch-Waxman action over generic apremilast tablets.
• Amgen relied on Otezla-related patents covering apremilast and later-expiring crystalline-form and related protection.
• USV's Paragraph IV certification triggered pre-launch patent litigation and the statutory FDA approval stay.
• The case ended through resolution and dismissal without a reported merits judgment.
• The public record does not establish whether the asserted patents would have been upheld or infringed.
• The settlement's commercial importance was the negotiated timing of generic apremilast entry.
• The case involved generic risk, not biosimilar risk.
• Otezla's high revenue made patent-term management and settlement timing material to Amgen's earnings exposure.

FAQs About Amgen v. USV and Otezla Patent Litigation

What is the case number for Amgen's USV apremilast lawsuit?

The case number is 1:22-cv-00387 in the U.S. District Court for the District of Delaware.

Did USV launch generic Otezla before patent expiration?

The public litigation record does not establish a pre-expiration commercial launch. The settlement and FDA approval timetable governed USV's ability to market its product.

Is apremilast a biologic or a small-molecule drug?

Apremilast is an orally administered small-molecule drug. Generic versions proceed through the ANDA pathway rather than the biosimilar pathway.

Does a Paragraph IV lawsuit prove that an Otezla patent is valid?

No. A Paragraph IV suit creates a framework for adjudicating validity, enforceability, and infringement. The Amgen-USV case ended without a reported merits ruling.

Why are crystalline-form patents important for generic apremilast?

Crystalline-form patents can cover the solid form used in the commercial tablet. A generic manufacturer may need to design around that form or establish that its proposed product does not infringe.

References

1. Amgen Inc. v. USV Private Limited, No. 1:22-cv-00387, U.S. District Court for the District of Delaware. Court docket and filings.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Otezla (apremilast) prescribing information. FDA.

4. U.S. Patent No. 6,962,940. (2005). Pharmaceutical compounds. U.S. Patent and Trademark Office.

5. U.S. Patent No. 8,193,197. (2012). Crystalline forms of apremilast. U.S. Patent and Trademark Office.

6. U.S. Patent No. 8,404,722. (2013). Methods for treating psoriasis and related disorders. U.S. Patent and Trademark Office.

7. Amgen Inc. (2023). 2022 annual report. U.S. Securities and Exchange Commission.